Apple, TKO, DigitalBridge, GlobalFoundries, Corcept Trending With Analysts

Analysts are intrested in these 5 stocks: ( (DBRG) ), ( (TKO) ), ( (GFS) ), ( (CORT) ) and ( (AAPL) ). Here is a breakdown of their recent ratings and the rationale behind them.

DigitalBridge Group has quickly shifted from a turnaround story to a classic merger-arbitrage play after SoftBank agreed to acquire the digital infrastructure investor for $16 per share in cash. Analyst Greg P. Miller, who had previously seen upside to $18 and believed many investors valued the stock in the mid-teens to around $20 or more, downgraded DigitalBridge to Hold, calling the agreed price “underwhelming” despite its roughly 15% premium to the latest close and a large premium to the longer-term average. He points out that the stock had traded near $17 in late 2024 and as high as the equivalent of $33 in 2021, and that potential carried-interest upside from monetizing data-center asset Switch could have justified a noticeably richer takeout price. Still, Miller sees strong strategic logic: SoftBank wants to use DigitalBridge’s portfolio to build the infrastructure backbone for advanced AI and so‑called “Artificial Super Intelligence,” and CEO Marc Ganzi will stay on to run the platform within SoftBank. In his view, however, public shareholders are effectively being cashed out before they can participate in that long-term AI upside.

A second voice, analyst Michael Elias, also moved to the sidelines, downgrading DigitalBridge to Hold while cutting his price target to match the $16 deal price. Elias notes that SoftBank’s offer values the company at roughly $4 billion in enterprise value, or about 26.8 times his 2026 forecast for fee-related earnings, squarely within the $15–$20 per share takeout range he had long seen as realistic. Having watched DigitalBridge spend much of 2025 in the headlines as a buyout candidate—first linked to private equity group 26North and then to SoftBank—he argues that any likely suitor has already had ample time to review the business, making a higher competing bid improbable. The deal, unanimously recommended by a special independent board committee and approved by the full board, is expected to close in the second half of 2026 after regulatory review, with DigitalBridge continuing as a separately managed platform under Ganzi. For investors, both analysts’ downgrades suggest the stock now trades more like a bond: with limited upside beyond the agreed cash price and risk tied mainly to deal closing and timing.

At TKO Group Holdings, home to the combined UFC and WWE franchises plus IMG, the tone is far more upbeat. Analyst Tyler Dimatteo has reiterated a Buy rating and lifted his price target to $250 from $235, arguing that 2025 exceeded expectations and that 2026 could be another strong year for sports and live entertainment. He highlights a string of key milestones: new media rights deals for UFC and WWE, accelerating sponsorship and partnership revenues, and the completion of the IMG acquisition—all while TKO has been returning cash to shareholders through buybacks and dividends. The stock is set to finish 2025 up nearly 75%, yet Dimatteo believes there is still “additional upside” as the investment story remains favorable, especially with the prospect of hundreds of basis points of margin expansion in 2026.

Dimatteo cautions that investors should brace for some volatility in the coming months as the market digests 2026 guidance. One potential near-term overhang is the highly publicized “White House fight” event, which management has framed more as a branding and marketing showcase for the U.S. 250th anniversary than as a meaningful revenue driver—essentially an operating cost center rather than a profit engine. If guidance for 2026 margins undershoots consensus, he sees scope for a short-term pullback. Still, his valuation framework, based on a sum-of-the-parts multiple of EBITDA across UFC, WWE, and IMG, supports a bullish long-run view, with a wide bull/bear range of $160–$305. Dimatteo’s segment assumptions call for robust revenue and healthy margins in each unit: UFC as the growth and profit powerhouse, WWE as a still-strong media and live-events brand, and IMG as a sizable but lower-margin contributor. For investors, the takeaway is that TKO is positioned as a premium way to play ongoing demand for live sports, global media rights inflation, and sponsorship growth—with some short-term choppiness possible, but a longer-term story that remains solidly intact.

GlobalFoundries tells a more cautious story, as analyst Matt Bryson has shifted his stance to Hold (Neutral) and trimmed his price target to $40 from $42. He still believes in the long-term potential of the specialty chip manufacturer, particularly its exposure to secure, U.S. and Europe–based production and the trend toward local supply chains. However, he now sees the semiconductor down cycle lasting longer than expected, which delays the point at which GlobalFoundries can fully benefit from stronger demand and better factory utilization. With about half of the company’s revenue tied to smart mobile devices and home and industrial IoT, he points to a tough near-term backdrop: handset makers are cutting build plans as rising memory costs push up device prices, and field checks in Taiwan suggest industrial and automotive chip demand remains weak with no clear recovery yet in sight.

Bryson also tempers expectations for a rapid policy-driven shift in chip manufacturing to the U.S. and allied regions. While GlobalFoundries’ U.S. and European footprint and minimal exposure to China are strategic positives, he notes that recently announced U.S. tariffs on Chinese semiconductors will not kick in until mid-2027, and political worries about pushing consumer prices higher could limit more aggressive measures that might otherwise accelerate demand for domestic capacity. The good news, he says, is that GlobalFoundries is still delivering results with margins near historical highs despite utilization below the ideal 95%+ level, and he still sees room for future margin and revenue gains once end markets recover and fabs fill up. The bad news is timing: the key drivers he once saw as nearer-term catalysts now look further out. For investors, his downgrade signals that while the long-term thesis around secure, non‑China chip supply remains intact, the stock may have limited upside until demand and policy momentum start to converge more clearly in GlobalFoundries’ favor.

Corcept Therapeutics faces a very different set of challenges, as regulatory and legal setbacks have prompted analyst Kalpit Patel to downgrade the stock to Sell (Underperform) and cut his price target to $30. The pivotal blow came when the FDA issued a Complete Response Letter (CRL) for relacorilant (rela) in Cushing’s syndrome, rejecting approval despite the drug meeting its primary endpoint in the GRACE trial and generating supportive data in the GRADIENT study. Patel notes that relacorilant had been expected to become Corcept’s “bread winner,” eventually offsetting mounting threats to the company’s current flagship drug Korlym. With the FDA now asking for additional evidence of effectiveness, he believes the most realistic path forward would involve another major trial—an expensive, time-consuming effort whose outcome is uncertain and may not change the agency’s overall risk‑benefit view. As a result, he removes Cushing’s-related sales for relacorilant from his valuation.

That puts the spotlight back on Korlym, where Patel sees a series of looming headwinds. Generic competition from Teva could start to bite as early as next year, pressuring both volume and pricing, just as ongoing patent infringement and antitrust lawsuits move closer to resolution. Historically he viewed these legal battles as a background overhang that would be mitigated once relacorilant took over as the primary revenue driver. With the Cushing’s indication now off the table for the foreseeable future, he expects adverse legal or competitive outcomes to have much more direct impact on Corcept’s earnings power and valuation. Not all of relacorilant’s potential is gone: Patel maintains his positive stance on its prospects in ovarian cancer, where earlier data showed promise and a key regulatory decision is scheduled for mid‑2026, with additional phase 2 work underway in various gynecologic cancer settings. Still, the core message for investors is that Corcept has abruptly shifted from a transition story—moving patients from Korlym to relacorilant—to a company whose main cash cow is exposed on multiple fronts, while its would‑be successor faces a long, uncertain path.

In contrast, Apple continues to be seen as a high‑quality, core holding, but without enough near‑term upside to justify a bullish call at current prices. Analyst Melissa Fairbanks has resumed coverage with a Hold (Market Perform) rating, arguing that the market already fully reflects Apple’s strengths in hardware, services, and ecosystem stickiness. The installed base has swelled to roughly 2.4 billion users, which supports recurring revenue but also makes it harder for incremental product upgrades to move the needle on growth. Fairbanks credits the iPhone 17 cycle with helping Apple regain momentum, especially as deeper integration of on‑device generative AI capabilities and secure cloud processing promises to enhance Siri and key productivity apps. She expects this to drive a healthy upgrade wave after several lackluster years, but she feels the associated earnings boost is largely priced in.

Apple’s services business remains a bright spot, making up about 26% of fiscal 2025 revenue and growing faster than hardware with higher margins. Fairbanks sees services as a key driver of smoother, more predictable cash flows over time and an anchor that reduces the risk that users switch to competing ecosystems. Even so, she still characterizes Apple as primarily a hardware-driven story, with stock performance tied to the ebb and flow of iPhone cycles. Her forecasts call for 8% top-line growth and $8.19 in GAAP EPS in fiscal 2026, followed by 7% growth and $9.13 EPS in 2027, helped by strong services expansion and steady iPhone sales. But with Apple shares trading around 31 times her 2027 earnings estimate—several turns above the five-year average, and a similar multiple on free cash flow—she sees little room for multiple expansion and limited scope for outperformance versus other large-cap names. For investors, the message is clear: Apple remains a solid, defensive cornerstone of many portfolios, but at today’s valuation it looks more like a hold than a fresh opportunity for outsized gains unless new, unexpected catalysts emerge.